… The purpose of this study was to compare downstream and upstream oral P2Y 12
inhibitors administration strategies in patients with non–ST-segment elevation acute coronary …

… consistent platelet inhibition represents the cornerstone of pharmacologic treatment in the
early hours of ST-segment elevation myocardial infarction (STEMI). Oral P2Y 12 inhibitors are …

Objectives : The study sought to compare the clinical efficacy and safety of P2Y 12 inhibitors
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …

… of stronger platelet inhibition regimens versus standard … Platelet reactivity variability
before P2Y12 blockade and its … experience obtained with P2Y12 inhibitors administered as …

The efficacy and safety of novel oral P2Y 12 receptor inhibitors (prasugrel and ticagrelor)
are subjects of contention in patients with ST-segment elevation myocardial infarction (STEMI) …

… P2Y12 inhibitor in adjunct to aspirin, before performing the coronary angiography and defining
the coronary anatomy (1). Initiation of an oral P2Y12 inhibitor … the oral P2Y12 inhibitor is …

… assessed platelet inhibition in 37 patients … inhibition at T3 (VASP-PRI 78.2 vs 23.4% without
morphine; p = 0.0116) and T4 (33.1 vs 11.0%; p = 0.0057). In conclusion, platelet inhibition …

… 9 Starting a P2Y12 inhibitor upfront carries a hypothetical risk of overtreatment in patients in
whom the diagnosis is uncertain. It may be perceived that waiting until the coronary anatomy …

… Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation …
The timing of oral P2Y12 inhibitor administration in patients with non-ST elevation acute …

… We determined national utilization rates of P2Y12 inhibitors at … on hospital quartile of potent
P2Y12 inhibitor use. Rates of … The median hospital usage rate for newer P2Y12 inhibitors …